Our xenograft model portfolio is evaluated on a regular basis for response to standards of care and this data is available for designing combination studies.
Our scientific staff can assist in selecting the most appropriate model for your agent. Complete profiling of agents can be carried out in a variety of tumor types or in combination with the appropriate clinical agent.
Efficacy evaluation can be combined with:
- Hematology (CBC/Diff) analysis
- Pharmacokinetic or bioavailability sampling and analysis
- Histopathology or tissue sampling
- Biomarker screening, sampling or evaluation
MODELS WITH PROFILE
Histotype Cell Line* Bladder SW780 Brain SF-295, SK-N-AS, U87 MG, U251 Breast BT474, HCC-1806, HCC-1954, JIMT-1, MCF-7, MDA-MB-231 Colon CL-34, COLO 205, DLD-1, HCT 116, HCT-15, HT-29, LoVo, LS-174T, LS411N, RKO, SW48, SW480, SW620 Epithelial A-431 Gastric N87, SNU-5 Head and Neck FaDu Leukemia HL-60, MOLM-13, MOLT-4, MV4-11, RS4;11, SET2, THP-1 Liver Hep3B, HuH-7, SNU-398 Lung (Non-small cell) A-427, A549, H1299, H1975, H226, H23, H292, H460, H520, H522, H647, H727, H810, HCC-44, NCI-H2122, SK-MES-1 Lung (Small cell) H69, H82, H211, H526, SHP-77, DMS 114 Lymphoma Daudi, DoHH-2, Granta 519, JEKO-1, KARPAS-299, MOLT-4, Raji B, Ramos, REC-1, RL, SU-DHL-4, WSU-DLCL2 Melanoma A2058, A375, IGR-37, UACC-62 Mesothelioma MSTO-211H Multiple Myeloma H929, OPM-2, RPMI 8226 Neuroblastoma SKNAS Ovarian A2780, IGR0V1, OVCAR-3, OVCAR-5, SK-OV-3, TOV-21G Pancreas BxPc-3, HPAC, HPAF II, KP4, MIA PaCa-2 Prostate 22Rv.1, PC3 Renal 786-0, G-401, G-402 Sarcoma HT-1080, SJSA-1 Thyroid 8505C, FTC-238 Uterine ECC-1, MFE-280 * Note: Specially requested lines can be developed if a model of interest is not among those listed above.
MODELS WITHOUT PROFILE
Although the models listed below have not yet been profiled for response to current standards of care, tumor growth curve data is available.
Histotype Cell Line* Adrenal H295R Breast HCC70 Ewing's Sarcoma RD-ES Gastric MKN-45 Leukemia HEL92.1.7, K-562, Kasumi-1 Lung COR-L23, NCI-H1963, H2009, H1581, H1993, H441 Lymphoma Mino, Namalwa Melanoma CHL-1, COLO 800, IGR-1, IGR-37 Ovarian OV-90 Prostate DU145, LNCaP, VCaP Thyroid K1 Uterine HEC-1-A, HEC-1-B * Note: Specially requested lines can be developed if a model of interest is not among those listed above.